Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Startseite
  2. Aktien
  3. Deutschland
  4. Xetra
  5. MorphoSys AG
  6. News
  7. Andere Sprachen
    MOR   DE0006632003   663200

MORPHOSYS AG

(663200)
  Bericht
Verzögert Xetra  -  17:35:29 27.01.2023
18.15 EUR   +0.83%
25.01.Biopharma- und Tech-Aktien führen europäische Aktien leicht nach unten
MT
24.01.Pharma-Aktien belasten europäische Aktien im Dienstagshandel
MT
23.01.Pvr : MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
EQ
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über MORPHOSYS AG
25.01.Biopharma, Tech Stocks Lead European Equities Slightly Lower
24.01.Pharma Stocks Weigh Down European Equities in Tuesday Trading
19.01.Pharma Stocks Weigh Down European Equities in Thursday Trading
13.01.European Equities Rise in Friday Trading, ADRs End Week Up 2%
11.01.Pharma Stocks Pull European Equities Lower in Wednesday Trading
09.01.MorphoSys Expects Topline Data From Phase 3 Trial of Bone Marrow Cancer Therapy in Earl..
09.01.MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in ..
09.01.Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib..
06.01.Bolsa de Madrid: Inversores un poco confusos
06.01.Des investisseurs un peu déboussolés
06.01.Avis d'analystes du jour : Safran, Danone, Novartis, Nestlé, Ne..
05.01.Pharma Stocks Lead European Equities Lower in Thursday Trading
05.01.Morphosys sales target for Monjuvi weighs on share price
05.01.Morphosys: 2023 only best-case growth for cancer drug Monjuvi
05.01.Morphosys sees only best-case growth for cancer drug Monjuvi in 2023
05.01.MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financ..
05.01.Ad Hoc : MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 20..
04.01.European Equities Continue Strong Start to 2023 in Wednesday Trading
2022InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Tre..
2022European Equities Rise Modestly in Friday Trading, End Week Up 1%
2022Bolsa de Madrid: El consumidor estadounidense despierta a Papá Noel
2022Le consommateur américain réveille le Père Noël
2022Avis d'analystes du jour : Logitech, Alcon, Bolloré, Basic-Fit,..
2022Global markets live: 3M Company, General Motors, Wells Fargo, Nike, ..
2022European Equities Follow US Markets Higher in Wednesday Trading
2022Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
2022Ça se présente mal pour le rally de fin d'année
2022Bolsa de Madrid: Las cosas pintan mal para el rally de fin de año
2022En Direct des Marchés : Alstom, Technip Energies, Eutelsat, Valeo,..
2022MorphoSys CFO to Quit in March 2023
2022MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave
2022MorphoSys AG Announces Sung Lee, Management Board Member, Decided to Leave
2022German pharma company MorphoSys's finance head to step down
2022Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
2022European Equities Buoyed by Financial, Pharma Stocks in Tuesday Trading
2022European Equities Lose Early Momentum, Remain Relatively Flat in Monday Trading
2022La rassegna settimanale di Borsa : "La prudenza non è m..
2022Le point hebdo de l'investisseur : Prudence est mère de..
2022El boletín semanal del inversor : El rallye de fin de añ..
2022Wekelijks beursoverzicht : Voorzichtigheid geboden aan dit jaa..
2022European Equities Sharply Lower With Pharma, Telecoms Most Active Sectors
2022Biotechnology Gains Lead European Equities Higher in Wednesday Trading
2022European Equities Follow US Markets Sharply Higher in Tuesday Trading
2022MorphoSys AG Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients fro..
2022Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Incl..
2022MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Incl..
2022MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from F..
2022European Equities Rise Modestly Friday, But End Week Lower
2022Global markets live: Glencore, Apple, Netflix, Tesla, Amazon...
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
2022EN DIRECTO DESDE LOS MERCADOS: Sabadell, Iberdrola, Glenco..
2022En Direct des Marchés : Sanofi, Engie, Airbus, EuroAPI, Tesla, App..
2022Novartis Signs Licensing Deal for MorphoSys Unit's Cancer Program
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
2022European Equities Move Lower to End Strong Month, Week Lower
2022Afr : MorphoSys AG: Preliminary announcement of the publication of quarterly reports and q..
2022Morphosys Ag : Financial Calendar 2023
2022Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K
2022Dd : MorphoSys AG: Krisja Vermeylen, buy
2022Morphosys : Notification of managers`transactions according to article 19 MAR - Form 6-K
2022Dd : MorphoSys AG: Dr. Marc Cluzel, buy
2022MorphoSys AG Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2022MorphoSys AG Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2022Earnings Flash (MOR) MORPHOSYS AG Reports Q3 Revenue EUR95.8M
2022MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
2022MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
2022Earnings Flash (MOR) MORPHOSYS AG Posts Q3 Loss EUR-3.60
2022European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
2022European Markets Move Higher Helped by Upbeat US Inflation Data
2022Top Midday Decliners
2022European ADRs Continue to Trend Higher in Monday Trading
2022MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant..
2022Wall Street Set to Open Lower After Red Hot Week; Fed Gov Warns Inflation Fight Not Ove..
2022Sector Update: Health Care Stocks Advance Pre-Bell Monday
2022Sector Update: Health Care
2022US Futures Nudge Lower Premarket as Fed Governor Warns Inflation Fight Not Over
2022Top Premarket Decliners
2022MorphoSys Shares Slide After Roche's Alzheimer's Drug Trial Fails
2022Roche's Alzheimer's drug fails to meet goal in long awaited trial
2022MorphoSys Says Therapeutic Candidate for Alzheimer's Disease Missed Primary Endpoint in..
2022MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gant..
2022Roche's Alzheimer's drug fails to meet goal in long awaited trial
2022Ad Hoc : MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program fo..
2022Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Cal..
2022Invitation to MorphoSys' Third Quarter and First Nine Months 2022 Results Conference Ca..
2022European ADRs Move Lower in Wednesday Trading
2022MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Present..
2022European ADRs Move Higher in Tuesday Trading
2022European ADRs Move Higher in Friday Trading
2022MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting..
2022GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Oti..
2022MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-02..
2022MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)..
2022GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Ot..
2022European ADRs Move Higher in Monday Trading
2022MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
2022Opiniones de los analistas del día: BP, Akzo Nobel, R..
2022European ADRs Move Higher in Friday Trading
2022Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022
2022MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance..
Anstehende Termine für MORPHOSYS AG